Nanoliposomal Irinotecan is named as a drug or biological intervention in 2 clinical trials in our China, UK and USA trial registers, 2 of which are recruiting. Lead sponsors include AstraZeneca (1) and Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1). Registered phase: Phase 2. Conditions studied include Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06219941 | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer |
Phase 2 | Recruiting |
| NCT06405490 | NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (ClinicalTrials.gov ↗) Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin |
Phase 2 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastric Cancer | 1 |
| Gastroesophageal Junction Cancer | 1 |
| Biliary Tract Cancer | 1 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Nanoliposomal Irinotecan | 1 |
| Cadonilimab | 1 |
| Oxaliplatin | 1 |
| Capecitabine | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Register | Nanoliposomal Irinotecan trials |
|---|---|
| Clinical trials in China | 2 |
| Clinical trials in UK | 1 |
| Clinical trials in USA | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nanoliposomal Irinotecan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nanoliposomal Irinotecan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.